previous
discov
geldanamycin
ligand
heat
shock
protein
effect
inhibit
herp
simplex
viru
type
replic
vitro
vivo
mous
enceph
model
studi
demonstr
geldanamycin
strong
activ
herp
simplex
viru
type
vitro
vivo
mous
vagina
model
mous
vagina
model
administr
geldanamycin
suspens
vagina
viru
infect
protect
infect
mice
death
increas
averag
surviv
day
dosedepend
manner
geldanamycin
also
significantli
reduc
viru
shed
mous
vagina
geldanamycintr
group
statist
signific
compar
infect
control
group
highdos
group
geldanamycin
mg
kg
better
acyclovir
group
mg
kg
geldanamycin
vagin
administr
mockinfect
group
show
signific
bodi
weight
loss
although
geldanamycin
strong
antivir
activ
variou
dna
rna
virus
geldanamycin
suitabl
system
administr
high
toxic
consid
geldanamycin
candid
topic
usag
treatment
herp
simplex
viru
type
infect
herp
simplex
viru
type
member
asubfamili
human
herp
virus
infect
human
genit
tract
mucosa
lead
sexual
transmit
diseas
genit
herp
one
preval
sexual
transmit
diseas
worldwid
especi
immunocompromis
popul
infect
increas
risk
hiv
infect
moreov
transmiss
occur
via
sexual
perinat
rout
asymptomat
viral
shed
sever
drug
licens
treatment
hsv
infect
target
viral
dna
polymeras
rapid
emerg
drugresist
viru
strain
develop
effect
therapi
hsvcaus
diseas
becom
import
especi
develop
novel
therapeut
agent
differ
mechan
action
geldanamycin
ga
antibiot
primari
target
adpatpbind
site
heat
shock
protein
ga
bind
block
activ
chaperon
function
result
rapid
degrad
client
protein
via
ubiquitinproteasom
pathway
client
protein
includ
aktpkb
prb
steroid
hormon
receptor
specif
inhibitor
ga
deriv
display
antitumor
activ
multitud
anim
model
deriv
ga
clinic
trial
treatment
variou
cancer
includ
multipl
myeloma
phase
iii
breast
renal
thyroid
ovarian
pancrea
phase
ii
pediatr
solid
tumor
phase
field
virolog
import
sever
viru
replic
includ
hbv
hcv
hcmv
hsv
vsv
vaccinia
viru
coxsacki
viru
rhinoviru
ebola
viru
shown
specif
inhibitor
ga
block
replic
virus
mention
cell
cultur
system
also
confirm
ga
significantli
decreas
mortal
increas
mean
surviv
day
mice
mous
enceph
model
studi
activ
ga
evalu
cell
cultur
genit
model
mice
infect
femal
kunm
mice
week
age
g
weight
obtain
center
experiment
anim
chines
academi
medic
scienc
beij
china
mice
maintain
anim
facil
institut
medicin
biotechnolog
chines
academi
medic
scienc
peke
union
medic
colleg
permit
ethic
committe
anim
experi
institut
medicin
biotechnolog
mice
distribut
randomli
group
mice
per
group
wood
chip
bed
provid
chow
pellet
tap
water
ad
libitum
mice
hous
humid
lightdark
cycl
african
green
monkey
kidney
vero
cell
strain
obtain
institut
virolog
chines
academi
medic
scienc
beij
china
cell
grown
eagl
minimum
essenti
medium
supplement
heat
inactiv
fetal
bovin
serum
supplement
penicillin
u
ml
streptomycin
mg
ml
lglutamin
propag
vero
cell
three
cycl
freezethaw
brief
centrifug
supernat
aliquot
kept
use
viru
titer
supernat
determin
plaqu
format
assay
ga
purchas
sigma
chemic
st
loui
mo
usa
dissolv
dmso
mm
stock
solut
dilut
cultur
medium
use
acyclovir
acv
kindli
provid
depart
chemic
drug
chines
state
drug
administr
dissolv
steril
water
stock
solut
dilut
cultur
medium
salin
use
vero
cell
exponenti
growth
seed
micropl
falcon
oxnard
ca
usa
densiti
cell
per
well
follow
addit
ga
final
concentr
mm
incub
h
cell
viabil
assess
mtt
assay
tetrazolium
bromid
cytotox
determin
duplic
experi
repeat
three
time
ident
condit
cc
defin
concentr
inhibit
cellular
growth
comparison
untreat
control
calcul
reed
muench
method
confluent
vero
cell
grown
sixwel
plate
infect
pfu
strain
per
well
adsorpt
cell
monolay
wash
phosphatebuff
salin
maintain
cultur
medium
mem
contain
methylcellulos
without
variou
concentr
ga
incub
co
plate
fix
buffer
formalin
aqueou
stain
crystal
violet
methanol
plaqu
count
ic
determin
reed
muench
method
confluent
cell
cultur
grown
micropl
infect
duplic
consecut
dilut
viral
sampl
collect
mous
differ
group
adsorpt
monolay
wash
phosphatebuff
salin
incub
mainten
medium
mem
plu
fetal
bovin
serum
viral
cytopath
effect
observ
tcid
determin
reed
muench
method
use
mous
vagin
model
infect
modif
studi
vivo
efficaci
ga
briefli
mice
vagina
extens
clean
steril
cotton
swab
solut
contain
pfu
ml
prepar
mem
inocul
intravagin
viru
dose
use
infect
experi
result
high
rate
mortal
vagina
model
mice
per
group
mice
treat
intravagin
three
differ
concentr
ga
suspens
mg
kg
h
post
infect
three
time
day
day
procedur
appli
acv
group
mg
kg
infect
control
group
vehicl
anim
monitor
morbid
mortal
day
mice
randomli
group
six
group
color
label
inocul
intravagin
ga
treatment
done
way
describ
except
durat
treatment
day
sampl
vagin
secret
mice
group
collect
individu
h
post
infect
sampl
cotton
steril
swab
wet
mem
put
vagina
gentli
swab
cotton
swab
put
test
tube
mem
antibiot
penicillin
u
ml
streptomycin
mg
ml
soon
possibl
sampl
frozen
titrat
perform
cytopath
effect
assay
uninfect
mice
group
treat
dose
infect
mice
group
mice
weigh
individu
day
statist
signific
estim
accord
w
analysi
mortal
data
kaplanmei
analysi
mean
surviv
day
ttest
analysi
bodi
weight
use
spss
softwar
spss
softwar
pvalu
less
consid
signific
vitro
activ
ga
use
plaqu
reduct
assay
studi
activ
ga
ga
significantli
inhibit
replic
vero
cell
dosedepend
manner
figur
ic
valu
ga
mm
cytotox
effect
ga
vero
cell
measur
convent
mtt
method
cc
mm
therapeut
index
ga
infect
vero
cell
better
known
hsv
drug
acv
vivo
activ
ga
evalu
vivo
activ
ga
mous
vagina
model
preliminari
experi
kunm
mice
inocul
variabl
dose
find
adequ
viru
dose
would
mous
vagin
model
symptom
ill
observ
mice
vagin
infect
includ
puff
fur
arch
back
feebl
gait
hind
limb
paralysi
wet
fur
stain
fece
anu
vagin
region
swollen
red
vulva
hair
loss
skin
lesion
anu
vagin
region
hind
limb
death
diseas
sign
evolv
inflamm
red
hair
loss
ulcer
lesion
genit
region
final
flaccid
paralysi
studi
infect
mice
die
around
day
post
infect
treatment
involv
administr
ga
suspens
vagina
infect
mg
kg
tid
day
protect
infect
mice
death
increas
averag
surviv
day
dosedepend
manner
differ
statist
signific
compar
untreat
infect
control
tabl
shown
figur
ga
also
significantli
reduc
shed
mice
vagina
sampl
vagin
secret
mice
group
collect
individu
h
post
infect
titer
determin
cytopath
effect
assay
ga
mg
kg
treatment
reduc
shed
time
compar
infect
control
group
respect
acv
mg
kg
treatment
reduc
shed
time
compar
infect
control
group
summari
ga
effici
inhibit
replic
vivo
show
therapeut
effect
better
acv
mous
growth
impact
ga
mous
vagin
model
uninfect
mice
group
treat
dose
infect
mice
group
mice
weigh
individu
day
shown
tabl
ga
vagin
administr
group
effect
mice
growth
weight
measur
crucial
role
mainten
conform
stabil
activ
cellular
local
sever
key
protein
involv
cell
signal
prolifer
surviv
novel
target
cancer
therapi
import
sever
viru
replic
specif
inhibitor
ga
block
replic
virus
mention
cell
cultur
system
antivir
drug
clinic
use
target
specif
viral
protein
ensur
specif
limit
toxic
though
great
progress
made
approach
obviou
antivir
drug
target
viral
protein
rel
narrow
antivir
spectrum
associ
emerg
drugresist
viral
strain
therefor
worthwhil
develop
new
antivir
differ
mechan
action
target
cellular
protein
relat
viru
replic
potenti
altern
approach
antivir
drug
develop
gener
inhibitor
broad
antivir
spectrum
less
likelihood
emerg
drug
resist
report
ga
ligand
heat
shock
protein
effect
inhibit
vitro
mechan
ga
explor
antivir
mechan
ga
appear
associ
inactiv
cell
cycl
restor
indic
ga
exhibit
broadspectrum
antivir
activ
fact
ga
exhibit
broadspectrum
antivir
activ
vsv
coxsacki
viru
sar
coronaviru
vitro
paper
report
ga
effect
inhibit
replic
hcmv
polioviru
rhinoviru
ga
exhibit
antivir
activ
vitro
report
mani
paper
relev
report
antivir
activ
ga
vivo
rel
rare
confirm
ga
effect
inhibit
vivo
previou
work
ga
administr
intraperiton
inject
subcutan
inject
exhibit
inhibitori
effect
mous
enceph
model
difficult
develop
system
administr
ga
low
water
solubl
high
hepatotox
lot
work
modif
ga
got
ga
deriv
discuss
structureact
relationship
ga
deriv
hcv
replicon
system
hcmv
hbv
coxsacki
viru
coxsacki
viru
overal
cytotox
test
deriv
decreas
compar
lead
compound
ga
antivir
activ
test
deriv
except
one
compound
also
reduc
compar
ga
see
supplementari
data
topic
treatment
import
cutan
hsv
infect
topic
treatment
reduc
system
exposur
drug
side
effect
reach
high
tissu
drug
level
studi
paper
focus
ga
topic
treatment
infect
mous
vagin
model
mous
vagina
model
administr
ga
suspens
vagina
viru
infect
protect
infect
mice
death
increas
averag
surviv
day
significantli
reduc
viru
shed
mous
vagina
dosedepend
manner
ga
effect
inhibit
replic
mous
vagin
model
topic
treatment
time
ga
vagin
administr
group
effect
mice
growth
weight
measur
highdos
group
ga
mg
kg
find
ga
effect
inhibit
replic
vitro
vivo
consolid
opinion
potenti
novel
target
antivir
research
although
cellular
protein
inhibitor
might
associ
appar
toxic
might
attenu
administr
properli
reduc
dosag
combin
viral
proteintarget
drug
importantli
target
may
provid
antivir
approach
refractori
develop
drug
resist
ga
suitabl
system
administr
toxic
consid
ga
candid
topic
usag
treatment
hsv
infect
